Implementation of biosecurity on equestrian premises: A narrative overview.

Vet J. February 2023;292(0):105950.

C R Crew¹, M L Brennan², J L Ireland³

¹ Department of Health and Social Care, 39 Victoria Street, London SW1H 0EU, UK; The Royal Veterinary College, Hawkshead Lane, Hatﬁeld, Hertfordshire AL9 7TA, UK.; ² School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Leicestershire LE12 5RD, UK.; ³ Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, The University of Liverpool, Leahurst Campus, Neston, Cheshire CH64 7TE, UK. Electronic address: Joanne.Ireland@liverpool.ac.uk.

Abstract

Biosecurity measures are designed to prevent the introduction and spread of pathogens, and play a vital role in the equine industry, controlling endemic diseases and reducing the threat of exotic disease incursion. Equestrian premises differ with respect to disease risks, biosecurity requirements and available facilities. This narrative review summarises reported frequency of implementation for selected biosecurity measures, as well as evidence relating to potential barriers to implementation of biosecurity on equestrian premises. Possible opportunities for improvement in the adoption of equine biosecurity measures are also discussed.

Keywords

Equine; Infection control; Quarantine; Transmission; Vaccination;

Article Tools:

Medline

Email to me

Archives Highlights:

Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.
The average duration of action of the 9.4 mg deslorelin implant was 790 ± 155 days (range 525-1140 days) with no significant difference in duration or efficacy depending on implantation sites. The 9.4 mg deslorelin implant causes pharmacological sterilization for about 2 years in female cats, is fully reversible, and caused no clinically relevant side effects when administered at both interscapular and periumbilical sites.

Coloration in Equine: Overview of Candidate Genes Associated with Coat Color Phenotypes.
In this review, we concisely categorize coat coloration in horses and donkeys, focusing on the biosynthesis and types of melanin involved in pigmentation. Moreover, the review explores how coat color relates to selective breeding and specific equine diseases, offering valuable insights for developing breeding strategies that enhance both the esthetic and health aspects of equine species.

The relationship between radiographic disc calcification score and FGF4L2 genotype in dachshunds.
Most dachshunds with 1 FGF4L2 copy have radiographic disc calcification scores that are associated with substantially lower risk of symptomatic disc disease. Radiographic disc calcification scores are similar in dachshunds with 0 and 1 FGF4L2 copies. Given the high allele frequency of FGF4L2, breeding to produce progeny with 1 FGF4L2 copy is expected to be a more achievable short-term goal for dachshund spinal health breeding programs than breeding for 0 copies. It is recommended that both K-n and FGF4L2 genotype status be considered when choosing dachshund breeding stock.

Challenges and Outlook of Veterinary Education in Iran: A Survey of Veterinary Students at Urmia University During the COVID-19 Pandemic.
Regarding future employment, 45.8% of participants wanted to start their own business or practice, whereas 54.2% preferred employment opportunities. A significant 81.6% of participants said they would consider emigrating to pursue better career prospects.

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.
On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority. By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54%, and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 µmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin).